Related references
Note: Only part of the references are listed.Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia
Elisa ten Hacken et al.
LEUKEMIA (2019)
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser et al.
LEUKEMIA (2019)
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Lan V. Pham et al.
CLINICAL CANCER RESEARCH (2018)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Paul M. Barr et al.
HAEMATOLOGICA (2018)
Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia
Ida K. Myhrvold et al.
Oncotarget (2018)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Paul M. Barr et al.
HAEMATOLOGICA (2018)
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
Lisa S. Chen et al.
BLOOD (2018)
Cryopreservation of primary B cells minimally influences their signaling responses
Johanne U. Hermansen et al.
SCIENTIFIC REPORTS (2018)
Targeted Therapies in CLL: Monotherapy Versus Combination Approaches
Maliha Khan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Nisar A. Amin et al.
CLINICAL CANCER RESEARCH (2017)
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Ahmed Hamed Salem et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia
Jon E. Arnason et al.
CURRENT ONCOLOGY REPORTS (2017)
Chronic lymphocytic leukaemia
Thomas J. Kipps et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Kallesh D. Jayappa et al.
BLOOD ADVANCES (2017)
Ibrutinib for treatment of chronic lymphocytic leukemia
Cory M. Vela et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
Chronic lymphocytic leukaemia
Lydia Scarfo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Chronic lymphocytic leukemia therapy: new targeted therapies on the way
Candida Vitale et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia
Jennifer R. Brown
SEMINARS IN ONCOLOGY (2016)
Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
Juraj Bodo et al.
ONCOTARGET (2016)
National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data
Andrea Lenartova et al.
CANCER MEDICINE (2016)
BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
Lorenzo Falchi et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2016)
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia
Gilad Itchaki et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Fabiola Cervantes-Gomez et al.
CLINICAL CANCER RESEARCH (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
The B-Cell Receptor Pathway: A Critical Component of Healthy and Malignant Immune Biology
Yiming Zhong et al.
SEMINARS IN HEMATOLOGY (2014)
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
Lyubov Zaitseva et al.
ONCOTARGET (2014)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Share Paper
